References
- Talbot J. M. Guidelines for the Scientific Review of Enteral Food Products for Special Medical Purposes. Federation of American Societies for Experimental Biology, Bethesda, MD 1990, prepared for the Food and Drug Administration under FDA Contract No. 223–88–2124 by the Life Sciences Research Office
- Fisher K. D., Talbot J. M., Carr C. I. A Review of Foods for Medical Purposes: Specially Formulated Products for Nutritional Management of Medical Conditions. Federation of American Societies for Experimental Biology, Bethesda, MD 1977, prepared for the Food and Drug Administration under Contract No. FDA 223–75–2090 by the Life Sciences Research Office
- Hattan D. G., Mackey D. R. A Review of Medical Foods: Enterally Administered Formulations Used in the Treatment of Diseases and Disorders. Food Drug Cosmetic Law Journal 1989; 44: 479–502
- Health Hazard Evaluation No. 1470, Food and Drug Administration Center for Food Safety and Applied Nutrition, 200 C St. SW. Washington, DC April 25, 1986
- FDA Enforcement Report. Rockville, MD August 23, 1989
- FDA Enforcement Report. Rockville, MD May 19, 1993
- FDA Enforcement Report. Rockville, MD July 28, 1993
- The United States Pharmacopeial Convention, Inc. USP DI, Drug Information for the Health Gore Professional, Volume I. Rand McNally, Taunton, MS 1996
- Subcommittee on the Tenth Edition of the RDA's, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances, 10th ed. National Academy Press, Washington, DC 1989
- Rept H. Nutrition Labeling and Education Act of 1990. June 13, 1990, 101–538, 101st Cong., 2dsess., 19
- Koretz R. L. A Critical Look at the Trials. Symposium #2, lmmunonutrition in the ICU. Proceedings of the 19th Clinical Congress, American Society for parenteral and Enteral Nutrition, Miami, FL, 1995; 97–103, This document is issued under sections 4, 5, and 6 of the Fair Packaging and Labeling Act (15 U.S.C: 1453,1454, 1455); sections 201, 301, 402,403, 404, 405, 409, 411, 412, 501, 502, 503, 505, and 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 342, 343,344, 345, 348, 350, 350a, 351,352, 353, 355, 371); and 21 U.S.C. 360ee(b)(3) (section 5(b) (3) of the Orphan Drug Amendments of 1988, as amended by Pub. L. 100–290)